Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Experimental: TU2218 + Pembrolizumab in Biliary Tract Cancer (BTC) expansion cohort Phase 2a

A RP2DC of TU2218 + Pembrolizumab administered, orally BID, for 2 weeks followed by 1 week of rest in 3-week cycles for TU2218 and intravenous 200mg once every 3 weeks for Pembrolizumab to patients with BTC to see whether TU2218 has potential to reverse resistance to an anti-PD-(L)1 agent.

Drug: TU2218 + Pembrolizumab

TU2218: Orally administered Pembrolizumab: Intravenously administered

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 28, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments